Shanghai Sci & Tech Committee and Shanghai Venture Capital Visited Zensun
2006-08-11
On March 18th, 2004, Zhu, Qigao and Dong, Shupei, Chair and Associate Chair of bio-therapeutical department, Shanghai Sci. and Tech. committee visited Zensun. Wang, Jianping, assistant Chair of modern biological and medicinal development office and Wang, Pingao CEO of Shanghai Venture Capital Co. Ltd. also joined this visit. They praised the results achieved by Zensun and provided constructive advice and promised the funding support for the research of Zensun’s two innovative drugs.
更多动态
Zensun is Collaborating with The Leibniz-Institut für Alternsforschung-Fritz-Lipmann-Institute.V. to Conduct a Preclinical Study of Neucardin® (recombinant human Neuregulin-1) for The Treatment of Schwannomas
ZENSUN ANNOUNCES THE INVESTIGATION OF NEUCARDIN FOR CHRONIC HEART FAILURE RECEIVES FAST TRACK DESIGNATION FROM THE US FDA
An International Multi-center Phase III Clinical Trial of Recombinant Human Neuregulin-1 is going to
